PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32740273-5 2020 SUMMARY: Optimal prevention of cisplatin-associated nausea and vomiting requires an aggressive approach with the use of a four-drug prophylactic regimen (NK1 receptor antagonist, 5-HT3 receptor antagonist, dexamethasone, olanzapine). Cisplatin 31-40 tachykinin receptor 1 Homo sapiens 154-166 34789076-11 2021 Although NK1 receptor antagonist (NK1RA) is generally recommended for cisplatin-containing chemotherapy, it can interact with variety drugs. Cisplatin 70-79 tachykinin receptor 1 Homo sapiens 9-21 33555084-9 2021 NK1 RAs were used in 45%/42%/19% of patients receiving cisplatin-/AC-/carboplatin-based chemotherapy, respectively; 18%/24%/7% received the guideline-recommended NK1 RA-5-HT3 RA-dexamethasone combination; no antiemetics were prescribed for 12% of the treatments. Cisplatin 55-64 tachykinin receptor 1 Homo sapiens 0-3 28691209-8 2017 CONCLUSION: The oral NK-1 receptor antagonist aprepitant could be effective for both acute and delayed CINV with cisplatin and for delayed CINV with carboplatin in Japanese gynecological cancer patients. Cisplatin 113-122 tachykinin receptor 1 Homo sapiens 21-34 27334131-2 2016 Patients receiving cisplatin routinely receive an NK1 RA-containing regimen with a resulting 14-22 % benefit in no emesis rates over a 5-HT3 RA/DEX control. Cisplatin 19-28 tachykinin receptor 1 Homo sapiens 50-53 26952945-20 2016 INTERPRETATION: To our knowledge, this is the first study to investigate safety and efficacy of a NK-1 receptor antagonist during 5 weeks of radiotherapy and concomitant weekly cisplatin. Cisplatin 177-186 tachykinin receptor 1 Homo sapiens 98-111 26476625-9 2016 NK1RAs were effective for CINV prevention in a small number of studies using high-dose chemotherapy as conditioning prior to stem cell transplant and cisplatin-based multiple-day chemotherapy (MDC). Cisplatin 150-159 tachykinin receptor 1 Homo sapiens 0-3 24641692-1 2014 BACKGROUND AND PURPOSE: Although substance P (SP) and neurokinin NK1 receptors have been reported to be involved in cisplatin-induced acute and delayed emesis, their precise roles remain unclear. Cisplatin 116-125 tachykinin receptor 1 Homo sapiens 65-68 24641692-8 2014 Within 24 h of the injection of cisplatin, PPT-A mRNA expression and SP release in the medulla were significantly increased; these findings lasted during the observation period and were inhibited by granisetron for up to 24 h. CONCLUSIONS AND IMPLICATIONS: The profiles of cisplatin-induced pica in rats are similar to clinical findings for cisplatin-induced emesis in humans, and we showed that SP production in the medulla and activation of NK1 receptors are involved in this cisplatin-induced pica. Cisplatin 32-41 tachykinin receptor 1 Homo sapiens 443-446 23001014-4 2013 Of the 12 time-points tested, significant increases in expression levels of NK(1) receptor mRNA in the shrew brainstem occurred at 2 and 28 h post-cisplatin injection, whereas intestinal NK(1) receptor mRNA was increased at 28 h. Shrew brainstem and intestinal substance P mRNA levels also tended to increase during the two phases. Cisplatin 147-156 tachykinin receptor 1 Homo sapiens 76-90 23863648-0 2013 [Comparative study of an antiemetic NK1 receptor-antagonist in lung cancer patients treated with divided doses for Cisplatin]. Cisplatin 115-124 tachykinin receptor 1 Homo sapiens 36-48 23001014-5 2013 Furthermore, expression levels of NK(1) receptor protein were significantly increased in the brainstem at 2, 8, and 33 h post-cisplatin. Cisplatin 126-135 tachykinin receptor 1 Homo sapiens 34-48 23001014-7 2013 The temporal enhancements in NK(1) receptor protein expression were mirrored by significant increases in the phosphorylation status of the brainstem ERK1/2 at 2, 8, and 33 h post-cisplatin. Cisplatin 179-188 tachykinin receptor 1 Homo sapiens 29-43 23001014-9 2013 Our results indicate associations between cisplatin"s peak immediate- and delayed-phase vomiting frequency with increased: (1) expression levels of NK(1) receptor mRNA and its protein level, and (2) downstream NK(1) receptor-mediated phosphorylation of ERK1/2 and PKA signaling. Cisplatin 42-51 tachykinin receptor 1 Homo sapiens 148-162 23001014-9 2013 Our results indicate associations between cisplatin"s peak immediate- and delayed-phase vomiting frequency with increased: (1) expression levels of NK(1) receptor mRNA and its protein level, and (2) downstream NK(1) receptor-mediated phosphorylation of ERK1/2 and PKA signaling. Cisplatin 42-51 tachykinin receptor 1 Homo sapiens 210-224 27713384-7 2010 Although NK1 antagonists behave in animals as broad-spectrum antiemetics against different emetogens including cisplatin-induced acute and delayed vomiting, by themselves they are not very effective against CINV in cancer patients. Cisplatin 111-120 tachykinin receptor 1 Homo sapiens 9-12 16872268-1 2006 The neurokinin-1 (NK1) receptor antagonist aprepitant has become part of standard antiemetic therapy for high-dose cisplatin. Cisplatin 115-124 tachykinin receptor 1 Homo sapiens 4-31 18628185-1 2004 Neurokinin-1 (NK-1) receptor antagonists are a new class of antiemetic agents that have activity in controlling cisplatin-induced acute and delayed emesis. Cisplatin 112-121 tachykinin receptor 1 Homo sapiens 0-28 14746859-0 2004 The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Cisplatin 143-152 tachykinin receptor 1 Homo sapiens 9-14 14746859-1 2004 In early clinical trials, the NK(1) receptor antagonist, aprepitant (EMEND(R)) was shown to improve the protection provided by the best available therapy (hereafter referred to as "standard therapy": a 5-HT(3) receptor antagonist and dexamethasone) against chemotherapy-induced nausea and vomiting over multiple cycles of cisplatin-based chemotherapy. Cisplatin 322-331 tachykinin receptor 1 Homo sapiens 30-44 14559891-0 2003 Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Cisplatin 145-154 tachykinin receptor 1 Homo sapiens 21-24 11497388-6 2001 A number of selective antagonists of the NK1 receptor have been synthesized and, when used in preclinical models, have demonstrated an ability to antagonize the emetic effects of a number of stimuli, including chemotherapy agents such as cisplatin. Cisplatin 238-247 tachykinin receptor 1 Homo sapiens 41-53 11700782-1 2001 BACKGROUND: The neurokinin-1 (NK1) receptor antagonists are a new class of agents designed to reduce the risk of emesis following chemotherapy, particularly with cisplatin. Cisplatin 162-171 tachykinin receptor 1 Homo sapiens 16-43 11700782-2 2001 Early data from double-blind randomised trials suggest that an orally administered NK1 antagonist can reduce the absolute risk of acute and delayed emesis following cisplatin by 20 and 30%, respectively. Cisplatin 165-174 tachykinin receptor 1 Homo sapiens 83-86 9804700-4 1998 Central hNK-1 receptor stimulation is also inhibited by the systemic preadministration of 17 as shown by its ability to block an NK-1 agonist-induced foot tapping response in gerbils (IC50 (4 h) = 0.04 +/- 0.006 mg/kg; IC50 (24 h) = 0.33 +/- 0.017 mg/kg) and by its antiemetic actions in the ferret against cisplatin challenge. Cisplatin 307-316 tachykinin receptor 1 Homo sapiens 8-13 9804700-4 1998 Central hNK-1 receptor stimulation is also inhibited by the systemic preadministration of 17 as shown by its ability to block an NK-1 agonist-induced foot tapping response in gerbils (IC50 (4 h) = 0.04 +/- 0.006 mg/kg; IC50 (24 h) = 0.33 +/- 0.017 mg/kg) and by its antiemetic actions in the ferret against cisplatin challenge. Cisplatin 307-316 tachykinin receptor 1 Homo sapiens 9-13 9182982-0 1997 Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. Cisplatin 66-75 tachykinin receptor 1 Homo sapiens 10-22 9063690-0 1997 The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret. Cisplatin 56-65 tachykinin receptor 1 Homo sapiens 15-27 9063690-1 1997 The activity of a selective tachykinin NK1 receptor antagonist, PD 154075 ([(2-benzofuran)-CH2OCO]-(R)-alpha-MeTrp-(S)-NHCH(CH3) Ph), was examined in radioligand binding studies, in a [Sar9,Met(O2)11]substance P-induced foot-tapping model in the gerbil, and in cisplatin-induced acute and delayed emesis in the ferret. Cisplatin 261-270 tachykinin receptor 1 Homo sapiens 39-51 9063690-18 1997 In conclusion, PD 154075 is a selective and specific high affinity NK1 receptor antagonist with good oral bioavailability which is effective against both acute and delayed emesis induced by cisplatin in the ferret. Cisplatin 190-199 tachykinin receptor 1 Homo sapiens 67-79